Literature DB >> 21969559

Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.

Christiane Meyer1, Alexandra Sevko, Marcel Ramacher, Alexandr V Bazhin, Christine S Falk, Wolfram Osen, Ivan Borrello, Masashi Kato, Dirk Schadendorf, Michal Baniyash, Viktor Umansky.   

Abstract

Tumor microenvironment is characterized by chronic inflammation represented by infiltrating leukocytes and soluble mediators, which lead to a local and systemic immunosuppression associated with cancer progression. Here, we used the ret transgenic spontaneous murine melanoma model that mimics human melanoma. Skin tumors and metastatic lymph nodes showed increased levels of inflammatory factors such as IL-1β, GM-CSF, and IFN-γ, which correlated with tumor progression. Moreover, Gr1(+)CD11b(+) myeloid-derived suppressor cells (MDSCs), known to inhibit tumor reactive T cells, were enriched in melanoma lesions and lymphatic organs during tumor progression. MDSC infiltration was associated with a strong TCR ζ-chain down-regulation in all T cells. Coculturing normal splenocytes with tumor-derived MDSC induced a decreased T-cell proliferation and ζ-chain expression, verifying the MDSC immunosuppressive function and suggesting that the tumor inflammatory microenvironment supports MDSC recruitment and immunosuppressive activity. Indeed, upon manipulation of the melanoma microenvironment with the phosphodiesterase-5 inhibitor sildenafil, we observed reduced levels of numerous inflammatory mediators (e.g., IL-1β, IL-6, VEGF, S100A9) in association with decreased MDSC amounts and immunosuppressive function, indicating an antiinflammatory effect of sildenafil. This led to a partial restoration of ζ-chain expression in T cells and to a significantly increased survival of tumor-bearing mice. CD8 T-cell depletion resulted in an abrogation of sildenafil beneficial outcome, suggesting the involvement of MDSC and CD8 T cells in the observed therapeutic effects. Our data imply that inhibition of chronic inflammation in the tumor microenvironment should be applied in conjunction with melanoma immunotherapies to increase their efficacy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21969559      PMCID: PMC3193202          DOI: 10.1073/pnas.1108121108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

Review 1.  Focus on melanoma.

Authors:  Alan N Houghton; David Polsky
Journal:  Cancer Cell       Date:  2002-10       Impact factor: 31.743

2.  Sustained exposure to bacterial antigen induces interferon-gamma-dependent T cell receptor zeta down-regulation and impaired T cell function.

Authors:  Noemí Bronstein-Sitton; Leonor Cohen-Daniel; Ilan Vaknin; Analía V Ezernitchi; Benny Leshem; Amal Halabi; Yael Houri-Hadad; Eugenia Greenbaum; Zichria Zakay-Rones; Lior Shapira; Michal Baniyash
Journal:  Nat Immunol       Date:  2003-09-21       Impact factor: 25.606

3.  Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression.

Authors:  Stephanie K Bunt; Pratima Sinha; Virginia K Clements; Jeff Leips; Suzanne Ostrand-Rosenberg
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

Review 4.  Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.

Authors:  Paolo Serafini; Ivan Borrello; Vincenzo Bronte
Journal:  Semin Cancer Biol       Date:  2005-09-15       Impact factor: 15.707

5.  CD3-zetachain expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patients.

Authors:  Sumiya Ishigami; Shoji Natsugoe; Koki Tokuda; Akihiro Nakajo; Hiroshi Higashi; Hirohumi Iwashige; Kuniaki Aridome; Shuichi Hokita; Takashi Aikou
Journal:  Cancer       Date:  2002-03-01       Impact factor: 6.860

Review 6.  Viagra (sildenafil citrate) and ophthalmology.

Authors:  Alan Laties; Eberhart Zrenner
Journal:  Prog Retin Eye Res       Date:  2002-09       Impact factor: 21.198

Review 7.  Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer?

Authors:  Theresa L Whiteside
Journal:  Cancer Immunol Immunother       Date:  2004-04-29       Impact factor: 6.968

Review 8.  Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.

Authors:  Licia Rivoltini; Matteo Carrabba; Veronica Huber; Chiara Castelli; Luisa Novellino; Piero Dalerba; Roberta Mortarini; Giuseppe Arancia; Andrea Anichini; Stefano Fais; Giorgio Parmiani
Journal:  Immunol Rev       Date:  2002-10       Impact factor: 12.988

9.  Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity.

Authors:  Cecilia Melani; Claudia Chiodoni; Guido Forni; Mario P Colombo
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

Review 10.  Immunity to cancer through immune recognition of altered self: studies with melanoma.

Authors:  José A Guevara-Patiño; Mary Jo Turk; Jedd D Wolchok; Alan N Houghton
Journal:  Adv Cancer Res       Date:  2003       Impact factor: 6.242

View more
  140 in total

1.  Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy.

Authors:  Courtney A Crane; Brian J Ahn; Seunggu J Han; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2012-03-09       Impact factor: 12.300

Review 2.  Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target.

Authors:  Elizabeth A Grimm; Andrew G Sikora; Suhendan Ekmekcioglu
Journal:  Clin Cancer Res       Date:  2013-07-18       Impact factor: 12.531

Review 3.  Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.

Authors:  Sabrin Husein Albeituni; Chuanlin Ding; Jun Yan
Journal:  Cancer J       Date:  2013 Nov-Dec       Impact factor: 3.360

4.  Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis.

Authors:  Jeremy D Waight; Colleen Netherby; Mary L Hensen; Austin Miller; Qiang Hu; Song Liu; Paul N Bogner; Matthew R Farren; Kelvin P Lee; Kebin Liu; Scott I Abrams
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

5.  Src, p130Cas, and Mechanotransduction in Cancer Cells.

Authors:  Hiroyuki Matsui; Ichiro Harada; Yasuhiro Sawada
Journal:  Genes Cancer       Date:  2012-05

6.  Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models.

Authors:  Mareike Grees; Adi Sharbi-Yunger; Christos Evangelou; Daniel Baumann; Gal Cafri; Esther Tzehoval; Stefan B Eichmüller; Rienk Offringa; Jochen Utikal; Lea Eisenbach; Viktor Umansky
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

7.  IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.

Authors:  Mauricio S Caetano; Huiyuan Zhang; Amber M Cumpian; Lei Gong; Nese Unver; Edwin J Ostrin; Soudabeh Daliri; Seon Hee Chang; Cesar E Ochoa; Samir Hanash; Carmen Behrens; Ignacio I Wistuba; Cinthya Sternberg; Humam Kadara; Carlos Gil Ferreira; Stephanie S Watowich; Seyed Javad Moghaddam
Journal:  Cancer Res       Date:  2016-04-01       Impact factor: 12.701

Review 8.  Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Authors:  Michael Hölzel; Anton Bovier; Thomas Tüting
Journal:  Nat Rev Cancer       Date:  2013-03-28       Impact factor: 60.716

9.  Tumor microenvironment and myeloid-derived suppressor cells.

Authors:  Viktor Umansky; Alexandra Sevko
Journal:  Cancer Microenviron       Date:  2012-12-16

10.  Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist.

Authors:  Susumu Fujiwara; Hiroshi Nagai; Noriko Shimoura; Shuntaro Oniki; Takayuki Yoshimoto; Chikako Nishigori
Journal:  J Invest Dermatol       Date:  2014-01-27       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.